ITEM 8.01/OTHER ITEMS: EXPLANATORY NOTE
Premier Biomedical, Inc. is filing this Form 8-K to reflect it has been
adversely impacted by COVID-19 (and continues to be so effected) and is
concurrently filing a Form NT ("not timely) per applicable rules that permit the
Form 10-Q for the period ended March 31 an additional 5 business days (to July
6). This Form 8-K also supplements registrant's disclosures re invoking the SEC
relief outlined below in its Amended Annual Report on Form 10-K for the year
ended December 31, 2019 (which was originally filed with the Securities and
Exchange Commission on May 15, 2020). We are filing this Amendment to provide
specific disclosure regarding our reliance on Release No. 34-88465 (the
"COVID-19 Release") and the impact of COVID-19 on registrant.
Except as set forth herein, no other changes are made to the Form 10-K. The Form
10-K continues to speak as of May 14, 2020. Registrant's inability to file its
Annual Report on Form 10-K for the year ended December 31, 2019 in a timely
manner was due to circumstances related to the COVID-19 global pandemic.
Registrant's inability to file on 10-Q for the quarter ended March 31, 2020 in a
timely manner is also due to circumstances related to the COVID-19 global
pandemic.
More specifically, our key personnel have been distracted by other priorities
associated with workplace closures, travel restrictions, school closures as well
as stay at home orders. Our work efficiencies have been negatively impacted.
We relied on the SEC's COVID-19 Release and associated order dated March 25,
2020 (which Release supersedes the SEC's order dated March 4, 2020--Release No.
34-88318) to extend the due date for the filing of our Form 10-K until 45 days
after the original due date. We relied on the same SEC order dated March 25,
2020 to extend the due date for the filing of our Form 10-Q until 45 days after
the original due date (to June 29, 2020) and, as permitted under the Release and
applicable SEC rules, to extend the 10-Q filing date for an additional 5
business days (to July 6, 2020).
In light of the current COVID-19 pandemic, registrant will be including an
appropriate Risk Factor in its FY 2020 10-K (due March 31, 2021), the following
disclosure will be our starting point (and as updated) to reflect subsequent
events impacting the Company:
We are unable to predict the full impact of COVID-19 on our company.
The SEC issued guidance March 25, 2020 that requires companies subject to its
jurisdiction to evaluate the impact of COVID-19 on the business and market of
Premier Biomedical, Inc. (hereafter "registrant" or "we"). Following the
Release's issuance, registrant has reviewed the Division of Corporation
Finance's Regulation CF Disclosure Guidance: Topic No. 9 as to COVID-19.
Preliminarily, registrant has concluded that, because of the nature of the
business, it does not believe the pandemic (on the facts and circumstances as
understood, currently and prospectively) is not expected to have a material
and/or adverse effect on our business activities. Of course, like all "forward
looking statements," the extent to which COVID-19 impacts our operations are not
fully knowable and are dependent upon future developments that may be outside of
our control.
Of course, assessing the evolving effects of COVID-19 and related risks requires
a "facts and circumstances" analysis. Disclosure about these risks and effects,
including how registrant's management is responding to them, is specific to
registrant's specific situation. As Premier Biomedical, Inc. assesses
COVID-19-related effects and considers those implications, we will update our
disclosures with respect to our present and future operations.
Our objective to have a continuing assessment of the impact of COVID-19 is facts
and circumstances driven. Consequently, registrant will continue to monitor the
rapidly evolving situation, seeking out guidance from authorities, including
federal state and public health authorities (and may take additional actions
based on their recommendations). In these dynamic circumstances, there may be
developments outside our control requiring us to adjust our operating plan.
2
© Edgar Online, source Glimpses